• The US FDA has approved Sesquient (fosphenytoin sodium for injection) for the treatment of status epilepticus in adult and pediatric patients
• Sedor is actively in discussions to license the rights to Sesquient for NA- EU- and other territories- except for the People’s Republic of China- where it has already been licensed
• Sesquient is the first and only FDA-approved room temperature stable fosphenytoin and can help HCPs to treat status epilepticus patients and reduce hospital costs associated with this condition

 ­ Ref: BusinessWire  | Image: Twitter